GlassScriptPhysician profile
Steven D Brown
NPI 1003888462
$6,481.02
in general payments reported to CMS, 2019-2025
48 companies · $768 in 2025
The $768 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $297 · 2021: $1,081 · 2022: $1,013 · 2023: $1,803 · 2024: $1,171 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810 · Travel and Lodging: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.63 |
| Travel and Lodging | $933.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $960.11 | 2023 | Procinch, Inspace, Iconix |
| Abbvie INC. | $699.94 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $682.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $635.82 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $520.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $517.24 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $351.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.17 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $222.27 | 2022-2024 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $191.93 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $117.86 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $112.22 | 2021-2023 | |
| Amgen INC. | $107.90 | 2019-2023 | Otezla, Repatha |
| Medtronic, INC. | $102.18 | 2023-2024 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $86.07 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.